PL215711B1 - Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji - Google Patents
Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycjiInfo
- Publication number
- PL215711B1 PL215711B1 PL360550A PL36055001A PL215711B1 PL 215711 B1 PL215711 B1 PL 215711B1 PL 360550 A PL360550 A PL 360550A PL 36055001 A PL36055001 A PL 36055001A PL 215711 B1 PL215711 B1 PL 215711B1
- Authority
- PL
- Poland
- Prior art keywords
- compound
- amyloid
- tissue
- binding
- group
- Prior art date
Links
- 238000011503 in vivo imaging Methods 0.000 title claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 14
- 238000003745 diagnosis Methods 0.000 title abstract description 8
- 230000003941 amyloidogenesis Effects 0.000 title description 10
- 230000002265 prevention Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 129
- 238000000034 method Methods 0.000 claims abstract description 64
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 108700028369 Alleles Proteins 0.000 claims abstract description 6
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims abstract description 6
- 201000010374 Down Syndrome Diseases 0.000 claims abstract description 5
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 4
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims abstract description 3
- 208000015756 familial Alzheimer disease Diseases 0.000 claims abstract description 3
- 230000027455 binding Effects 0.000 claims description 60
- 210000004556 brain Anatomy 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 238000001727 in vivo Methods 0.000 claims description 23
- 238000003384 imaging method Methods 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 17
- 230000002285 radioactive effect Effects 0.000 claims description 15
- 150000001412 amines Chemical group 0.000 claims description 13
- 238000001574 biopsy Methods 0.000 claims description 13
- 231100000252 nontoxic Toxicity 0.000 claims description 13
- 230000003000 nontoxic effect Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002600 positron emission tomography Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 9
- 210000001638 cerebellum Anatomy 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
- 238000000386 microscopy Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004611 spectroscopical analysis Methods 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000005388 cross polarization Methods 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012062 aqueous buffer Substances 0.000 claims description 2
- 238000000339 bright-field microscopy Methods 0.000 claims description 2
- 238000000799 fluorescence microscopy Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000035508 accumulation Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 44
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000002490 cerebral effect Effects 0.000 description 17
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 210000005013 brain tissue Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 11
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 9
- WKRCOZSCENDENK-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)aniline Chemical class C1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 WKRCOZSCENDENK-UHFFFAOYSA-N 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000282520 Papio Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- MSAHUKGXVPYUBT-UHFFFAOYSA-N 4-methoxy-n-(4-nitrophenyl)benzenecarbothioamide Chemical compound C1=CC(OC)=CC=C1C(=S)NC1=CC=C([N+]([O-])=O)C=C1 MSAHUKGXVPYUBT-UHFFFAOYSA-N 0.000 description 6
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 238000002610 neuroimaging Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical class NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 5
- HYKGLCSXVAAXNC-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=CC=C2S1 HYKGLCSXVAAXNC-UHFFFAOYSA-N 0.000 description 5
- ZSRQOGLPEUHLQQ-UHFFFAOYSA-N 6-methoxy-2-(4-nitrophenyl)-1,3-benzothiazole Chemical compound S1C2=CC(OC)=CC=C2N=C1C1=CC=C([N+]([O-])=O)C=C1 ZSRQOGLPEUHLQQ-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- DUEGOHNPUBPUIV-UHFFFAOYSA-N 3-methyl-4-nitrobenzoyl chloride Chemical compound CC1=CC(C(Cl)=O)=CC=C1[N+]([O-])=O DUEGOHNPUBPUIV-UHFFFAOYSA-N 0.000 description 4
- POFIKJKJPDPHTI-UHFFFAOYSA-N 4-(6-methoxy-1,3-benzothiazol-2-yl)-n,n-dimethylaniline Chemical compound S1C2=CC(OC)=CC=C2N=C1C1=CC=C(N(C)C)C=C1 POFIKJKJPDPHTI-UHFFFAOYSA-N 0.000 description 4
- SVOGNIBXGIPUDD-UHFFFAOYSA-N 4-[2-(1,3-benzothiazol-2-yl)ethenyl]aniline Chemical compound C1=CC(N)=CC=C1C=CC1=NC2=CC=CC=C2S1 SVOGNIBXGIPUDD-UHFFFAOYSA-N 0.000 description 4
- ILPFMFNLPIBAJF-UHFFFAOYSA-N 4-methoxy-n-(4-nitrophenyl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ILPFMFNLPIBAJF-UHFFFAOYSA-N 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- -1 BTP compound Chemical class 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- OEOPVJYUCSQVMJ-UHFFFAOYSA-N n,n-dimethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(C)C=C2S1 OEOPVJYUCSQVMJ-UHFFFAOYSA-N 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- ZTKDUAATMRBDMG-UHFFFAOYSA-N 4-(6-methoxy-1,3-benzothiazol-2-yl)-n-methylaniline Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC=C(OC)C=C2S1 ZTKDUAATMRBDMG-UHFFFAOYSA-N 0.000 description 3
- 102000001049 Amyloid Human genes 0.000 description 3
- 108010094108 Amyloid Proteins 0.000 description 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- YDIKCZBMBPOGFT-PWUSVEHZSA-N Malvidin 3-galactoside Chemical class [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-PWUSVEHZSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000007171 neuropathology Effects 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 3
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- VUMZNLOQJGKGNE-UHFFFAOYSA-N 2-amino-5-methylbenzenethiol Chemical compound CC1=CC=C(N)C(S)=C1 VUMZNLOQJGKGNE-UHFFFAOYSA-N 0.000 description 2
- FHJRKGXJBXPBGA-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-n-methylaniline Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC=CC=C2S1 FHJRKGXJBXPBGA-UHFFFAOYSA-N 0.000 description 2
- KLRFVKNLVPQVIN-UHFFFAOYSA-N 4-(6-methoxy-1,3-benzothiazol-2-yl)aniline Chemical compound S1C2=CC(OC)=CC=C2N=C1C1=CC=C(N)C=C1 KLRFVKNLVPQVIN-UHFFFAOYSA-N 0.000 description 2
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 2
- MVMOMSLTZMMLJR-FMIVXFBMSA-N 4-[(e)-2-(1,3-benzothiazol-2-yl)ethenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=NC2=CC=CC=C2S1 MVMOMSLTZMMLJR-FMIVXFBMSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000987 azo dye Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003458 metachromatic effect Effects 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- 239000008010 parenteral excipient Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- SICITCLFXRGKJW-IIZANFQQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 SICITCLFXRGKJW-IIZANFQQSA-N 0.000 description 1
- CQNPVMCASGWEHM-VMPITWQZSA-N (e)-3-[4-(dimethylamino)phenyl]prop-2-enoic acid Chemical compound CN(C)C1=CC=C(\C=C\C(O)=O)C=C1 CQNPVMCASGWEHM-VMPITWQZSA-N 0.000 description 1
- PMHQXRGRBMOZDU-UHFFFAOYSA-N 1,1-diaminoethanethiol Chemical compound CC(N)(N)S PMHQXRGRBMOZDU-UHFFFAOYSA-N 0.000 description 1
- SXYLTLZARIMRRU-OWOJBTEDSA-N 1-[(e)-3-chloroprop-1-enyl]-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(\C=C\CCl)C=C1 SXYLTLZARIMRRU-OWOJBTEDSA-N 0.000 description 1
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
- KEJBDGQLLLLBGE-UHFFFAOYSA-N 2-(4-nitrophenyl)-1,3-benzothiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC2=CC=CC=C2S1 KEJBDGQLLLLBGE-UHFFFAOYSA-N 0.000 description 1
- HWGHIOJSUIQXMU-UHFFFAOYSA-N 2-(4-nitrophenyl)-1,3-benzothiazole-6-carboxylic acid Chemical compound S1C2=CC(C(=O)O)=CC=C2N=C1C1=CC=C([N+]([O-])=O)C=C1 HWGHIOJSUIQXMU-UHFFFAOYSA-N 0.000 description 1
- CDPSBZCZTHXDSI-UHFFFAOYSA-N 2-[2-(4-nitrophenyl)ethenyl]-1,3-benzothiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=CC1=NC2=CC=CC=C2S1 CDPSBZCZTHXDSI-UHFFFAOYSA-N 0.000 description 1
- XBHOUXSGHYZCNH-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2S1 XBHOUXSGHYZCNH-UHFFFAOYSA-N 0.000 description 1
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- FRKPCXYPIHAOFI-UHFFFAOYSA-N 3-methylaniline Chemical compound [CH2]C1=CC=CC(N)=C1 FRKPCXYPIHAOFI-UHFFFAOYSA-N 0.000 description 1
- FHJRKGXJBXPBGA-BJUDXGSMSA-N 4-(1,3-benzothiazol-2-yl)-n-methylaniline Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=CC=C2S1 FHJRKGXJBXPBGA-BJUDXGSMSA-N 0.000 description 1
- XRTJYEIMLZALBD-UHFFFAOYSA-N 4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound S1C2=CC(C)=CC=C2N=C1C1=CC=C(N)C=C1 XRTJYEIMLZALBD-UHFFFAOYSA-N 0.000 description 1
- IQXJWOLTFBRYOK-UHFFFAOYSA-N 4-(dimethylamino)-3-methylbenzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1C IQXJWOLTFBRYOK-UHFFFAOYSA-N 0.000 description 1
- MVMOMSLTZMMLJR-UHFFFAOYSA-N 4-[2-(1,3-benzothiazol-2-yl)ethenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C=CC1=NC2=CC=CC=C2S1 MVMOMSLTZMMLJR-UHFFFAOYSA-N 0.000 description 1
- IRTVYZLHMRAYOX-UHFFFAOYSA-N 4-amino-2-methyl-5-sulfanylbenzoic acid Chemical compound CC1=CC(N)=C(S)C=C1C(O)=O IRTVYZLHMRAYOX-UHFFFAOYSA-N 0.000 description 1
- MHIJDDIBBUUVMD-UHFFFAOYSA-N 4-amino-3-sulfanylbenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1S MHIJDDIBBUUVMD-UHFFFAOYSA-N 0.000 description 1
- AZSOODMLINKHTI-UHFFFAOYSA-N 6-amino-2,3-dimethylbenzenethiol Chemical compound CC1=CC=C(N)C(S)=C1C AZSOODMLINKHTI-UHFFFAOYSA-N 0.000 description 1
- JOMSHNVRDUUQTJ-UHFFFAOYSA-N 6-iodo-2-(4-nitrophenyl)-1,3-benzothiazole Chemical class C1=CC([N+](=O)[O-])=CC=C1C1=NC2=CC=C(I)C=C2S1 JOMSHNVRDUUQTJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 description 1
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- UVTSZKIATYSKIR-RYUDHWBXSA-N Gly-Tyr-Glu Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O UVTSZKIATYSKIR-RYUDHWBXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 description 1
- PXUQTDZNOHRWLI-QOPOCTTISA-O Primulin Natural products O(C)c1c(O)c(OC)cc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O3)cc3c(O)cc(O)cc3[o+]2)c1 PXUQTDZNOHRWLI-QOPOCTTISA-O 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- HKNSIVFWRXBWCK-UHFFFAOYSA-N [N].NC1=CC=CC=C1 Chemical compound [N].NC1=CC=CC=C1 HKNSIVFWRXBWCK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- AZOPGDOIOXKJRA-UHFFFAOYSA-L chembl1817788 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C=2C=CC(=CC=2)N=NC=2C=C(C(O)=CC=2)C([O-])=O)C=C1 AZOPGDOIOXKJRA-UHFFFAOYSA-L 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N meta-toluidine Natural products CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002311 multiphoton fluorescence microscopy Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- WRKCIHRWQZQBOL-UHFFFAOYSA-N octyl dihydrogen phosphate Chemical compound CCCCCCCCOP(O)(O)=O WRKCIHRWQZQBOL-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N ortho-methyl aniline Natural products CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22760100P | 2000-08-24 | 2000-08-24 | |
| PCT/US2001/026427 WO2002016333A2 (en) | 2000-08-24 | 2001-08-24 | Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL360550A1 PL360550A1 (en) | 2004-09-06 |
| PL215711B1 true PL215711B1 (pl) | 2014-01-31 |
Family
ID=22853739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL360550A PL215711B1 (pl) | 2000-08-24 | 2001-08-24 | Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20020133019A1 (2) |
| EP (2) | EP2264018B1 (2) |
| JP (2) | JP5022554B2 (2) |
| CN (1) | CN1285582C (2) |
| AU (3) | AU8670201A (2) |
| BR (1) | BRPI0113470B8 (2) |
| CA (1) | CA2419420C (2) |
| CY (1) | CY1113311T1 (2) |
| DK (2) | DK1334091T3 (2) |
| ES (2) | ES2395721T3 (2) |
| HU (2) | HU230375B1 (2) |
| LT (1) | LTC1334091I2 (2) |
| NO (1) | NO330176B1 (2) |
| PL (1) | PL215711B1 (2) |
| PT (2) | PT1334091E (2) |
| RU (1) | RU2324686C2 (2) |
| SI (1) | SI1334091T1 (2) |
| WO (1) | WO2002016333A2 (2) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689753B1 (en) * | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
| AU2001239544A1 (en) * | 2000-03-22 | 2001-10-03 | Bf Research Institute, Inc. | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
| US7107092B2 (en) | 2000-08-21 | 2006-09-12 | The General Hospital Corporation | Methods for diagnosing a neurodegenerative condition |
| US7297326B2 (en) * | 2000-08-21 | 2007-11-20 | The General Hospital Corporation | Ocular diagnosis of Alzheimer's disease |
| RU2324686C2 (ru) * | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| US7270800B2 (en) | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| DE60128138T2 (de) * | 2000-11-02 | 2008-01-03 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| EP1478631A1 (en) * | 2001-11-28 | 2004-11-24 | AstraZeneca AB | Therapeutic compounds |
| US6774248B2 (en) | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| EP1820806A1 (en) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinity regions |
| AU2003239508A1 (en) | 2002-05-21 | 2003-12-12 | Bristol-Myers Squibb Company | Indole compounds useful as impdh inhibitors |
| WO2003106439A1 (ja) * | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬 |
| EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1547996A4 (en) * | 2002-08-30 | 2006-08-02 | Bf Res Inst Inc | DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN |
| CA2800237C (en) | 2002-12-19 | 2016-05-17 | The Scripps Research Institute | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| GB0229686D0 (en) | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase fluorination of benzothiazoles |
| PT1611115E (pt) * | 2003-03-14 | 2012-12-07 | Univ Pittsburgh | Compostos derivados de benzotiazole, composições e utilizações |
| CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| GB0307855D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| US20040223912A1 (en) * | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| WO2004100998A2 (en) | 2003-05-07 | 2004-11-25 | General Electric Company | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| WO2005016384A1 (ja) * | 2003-08-13 | 2005-02-24 | Bf Research Institute, Inc. | アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤 |
| CA2500358A1 (en) * | 2003-08-13 | 2005-02-24 | Bf Research Institute, Inc. | Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles |
| US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
| JP3877754B2 (ja) * | 2003-10-30 | 2007-02-07 | 株式会社同仁化学研究所 | アミロイド親和性化合物 |
| WO2005079863A1 (ja) * | 2004-02-25 | 2005-09-01 | Astellas Pharma Inc. | 血栓造影剤 |
| EP1756072A2 (en) | 2004-04-27 | 2007-02-28 | Wyeth | Purification of progesterone receptor modulators |
| GB0410448D0 (en) | 2004-05-11 | 2004-06-16 | Hammersmith Imanet Ltd | Purification methods |
| WO2005113523A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| JP2008505116A (ja) * | 2004-07-02 | 2008-02-21 | ユニバーシティー オブ ピッツバーグ | アミロイド沈着を伴う疾患の前駆形態の診断方法 |
| AU2005270026A1 (en) | 2004-07-02 | 2006-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019831A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006020156A2 (en) * | 2004-07-15 | 2006-02-23 | The General Hospital Corporation | Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease |
| WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| AU2006267176A1 (en) | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Cross-beta structure binding compounds |
| US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
| BRPI0613525A2 (pt) * | 2005-07-13 | 2011-05-31 | Crossbeta Biosciences Bv | métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica |
| CN101355940B (zh) * | 2005-09-16 | 2013-03-27 | 匹兹堡大学高等教育联邦体系 | 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法 |
| KR100778888B1 (ko) * | 2005-11-29 | 2007-11-28 | 재단법인서울대학교산학협력재단 | 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물 |
| WO2007063946A1 (ja) * | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 |
| CN101351458A (zh) * | 2005-12-01 | 2009-01-21 | 匹兹堡大学 | 作为促淀粉样变蛋白成像剂的同位素标记的苯并噻唑化合物 |
| WO2007075595A2 (en) * | 2005-12-20 | 2007-07-05 | Vertex Pharmacueticals Incorporated | Biofilm assay |
| US7781187B2 (en) * | 2005-12-30 | 2010-08-24 | Corning Incorporated | Fluorescent dyes |
| TW201018678A (en) | 2006-01-27 | 2010-05-16 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
| CA2641880C (en) | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| WO2007111179A1 (ja) * | 2006-03-28 | 2007-10-04 | Shiga University Of Medical Science | 神経難病の画像診断薬 |
| TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
| WO2008118122A2 (en) * | 2006-05-08 | 2008-10-02 | Molecular Neuroimaging, Llc | Compounds and amyloid probes thereof for therapeutic and imaging uses |
| US8303935B2 (en) | 2006-05-19 | 2012-11-06 | Nihon Medi-Physics Co., Ltd. | Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid |
| TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| WO2007148755A1 (ja) | 2006-06-21 | 2007-12-27 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物 |
| US8309054B2 (en) | 2006-08-03 | 2012-11-13 | Hammersmith Imanet Limited | Method for the purification of radiolabelled compounds |
| CA2670436A1 (en) | 2006-11-30 | 2008-06-05 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| CN101668560A (zh) * | 2006-12-07 | 2010-03-10 | 宾夕法尼亚大学理事会 | 乙炔衍生物及它们在结合和显像淀粉样斑块中的应用 |
| BRPI0806785A2 (pt) * | 2007-01-30 | 2011-09-13 | Ge Healthcare Ltd | ferramentas para auxiliar no diagnóstico de doenças neurodegenerativas |
| JP5258583B2 (ja) | 2007-02-13 | 2013-08-07 | 日本メジフィジックス株式会社 | 放射性画像診断剤の製造方法 |
| TW200901998A (en) | 2007-03-06 | 2009-01-16 | Astrazeneca Ab | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes |
| CN101293878B (zh) * | 2007-04-25 | 2010-12-15 | 中国科学院上海应用物理研究所 | 苯并噻唑苯胺类化合物及其制备方法和应用 |
| CA2685540C (en) | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| RU2475267C2 (ru) | 2007-08-30 | 2013-02-20 | Джи-И Хелткер Лимитед | Радиофармацевтическая композиция |
| KR20100091965A (ko) * | 2007-10-24 | 2010-08-19 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
| AU2008314871A1 (en) | 2007-10-26 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| KR20100101577A (ko) | 2007-10-30 | 2010-09-17 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 |
| CA2704168A1 (en) * | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
| US20090123373A1 (en) * | 2007-11-05 | 2009-05-14 | Yanming Wang | Amyloid-imaging agents |
| EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
| EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
| WO2009155024A1 (en) * | 2008-05-30 | 2009-12-23 | Merck & Co., Inc. | Novel substituted indoles |
| EP2304366A2 (en) * | 2008-05-30 | 2011-04-06 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
| AU2009260519A1 (en) | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted azabenzoxazoles |
| EP2687513B1 (en) | 2008-06-09 | 2020-12-02 | Ludwig-Maximilians-Universität München | Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| US20100099609A1 (en) * | 2008-07-28 | 2010-04-22 | Buck Institute For Age Research | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE |
| US9987379B2 (en) | 2008-09-30 | 2018-06-05 | Case Western Reserve University | Molecular probes for imaging of myelin |
| EP2365974B1 (en) * | 2008-11-06 | 2013-12-25 | SNU R&DB Foundation | Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same |
| US20100129290A1 (en) * | 2008-11-26 | 2010-05-27 | I.S.T. Corporation | Smart contrast agent and detection method for detecting transition metal ions |
| CN101598703B (zh) * | 2009-07-03 | 2012-08-22 | 中国人民解放军第三军医大学第一附属医院 | dGTpase蛋白在制备用于鉴别诊断唐氏胎儿药物中的应用 |
| FR2948685A1 (fr) * | 2009-07-30 | 2011-02-04 | Biomerieux Sa | Nouveaux substrats |
| US20110081428A1 (en) * | 2009-09-16 | 2011-04-07 | The Buck Institute For Age Research | Use of thioflavin-like compounds to increase life span and/or health span |
| DE102010045797A1 (de) | 2010-09-20 | 2012-03-22 | Klinikum Darmstadt Gmbh | Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel |
| WO2012041292A2 (de) | 2010-09-20 | 2012-04-05 | Klinikum Darmstadt Gmbh | Verbindungen für die diagnostik neurodegenerativer erkrankungen an der retina |
| AU2012259929B2 (en) | 2011-05-20 | 2016-08-04 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| CA2839199C (en) | 2011-06-24 | 2018-11-06 | Nihon Medi-Physics Co., Ltd. | Novel compound with amyloid affinity |
| WO2013027694A1 (ja) * | 2011-08-24 | 2013-02-28 | 国立大学法人京都大学 | コンフォメーション病診断用分子イメージングプローブ |
| RU2586330C2 (ru) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
| CN102526765B (zh) * | 2011-12-31 | 2014-07-30 | 郑州泰基鸿诺药物科技有限公司 | 一种Aβ斑块显像剂及其制备方法 |
| KR20130111082A (ko) * | 2012-03-30 | 2013-10-10 | 한미약품 주식회사 | 베타-아밀로이드 피브릴 형성 저해 효능을 갖는 아미노스티릴벤조퓨란 화합물 및 이를 함유하는 약학 조성물 |
| DK2890700T3 (en) | 2012-08-28 | 2018-03-12 | Univ Tuebingen Medizinische Fakultaet | HALOGENATED BENZOXAZINES AND THEIR USE |
| EP2890700B1 (de) * | 2012-08-28 | 2017-12-13 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Halogenierte benzoxazine und ihre verwendung |
| DK2767532T3 (en) | 2012-12-21 | 2016-09-12 | Nat Inst For Quantum And Radiological Science And Tech | New connection for reproduction of tau protein heavy in the brain. |
| US9246108B2 (en) | 2012-12-28 | 2016-01-26 | Dow Global Technologies Llc | Quinoline-benzoxazole derived compounds for electronic films and devices |
| WO2014127365A1 (en) | 2013-02-15 | 2014-08-21 | Case Western Reserve University | Psma ligands and uses thereof |
| CA2920068A1 (en) | 2013-09-26 | 2015-04-02 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyridin-7-amines as imaging tools |
| WO2015051188A1 (en) | 2013-10-02 | 2015-04-09 | Washington University | Heterocyclic molecules for biomedical imaging and therapeutic applications |
| EP4039255B1 (en) | 2014-04-24 | 2025-10-15 | Omoidesouzou Co. Ltd. | Amyloid fiber formation limiter or inhibitor |
| CN104059028B (zh) * | 2014-06-06 | 2020-10-16 | 北京智博高科生物技术有限公司 | 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用 |
| JP6498412B2 (ja) * | 2014-10-17 | 2019-04-10 | 国立大学法人群馬大学 | 新規チオフラビンｔ誘導体及びその利用 |
| US9842938B2 (en) | 2015-03-24 | 2017-12-12 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and display device including semiconductor device |
| WO2017156303A1 (en) | 2016-03-09 | 2017-09-14 | Case Western Reserve University | Radioligands for myelin |
| BR112018068066B1 (pt) * | 2016-03-11 | 2023-11-28 | Ac Immune Sa | Compostos bicíclicos e seu uso, composição diagnóstica e farmacêutica, misturas, métodos de coleção de dados para diagnóstico, para determinar uma predisposição a, para monitorar transtorno residual e para prever a capacidade de resposta de um paciente sofrendo de transtorno ou anormalidade associado com agregados de alfa-sinucleína, métodos para determinar a quantidade de agregados de alfa-sinucleína e para preparar um composto, kit teste e kit para preparar uma preparação radio farmacêutica |
| JP6765518B2 (ja) | 2016-09-29 | 2020-10-07 | コリア アトミック エナジー リサーチ インスティテュートＫｏｒｅａ Ａｔｏｍｉｃ Ｅｎｅｒｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | クルクミン誘導体、その製造方法、及びそれを含むベータ−アミロイドプラーク検出用光音響イメージング剤 |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| US11167283B2 (en) | 2018-05-04 | 2021-11-09 | University Of South Carolina | Dot blot box and use thereof |
| TW201946624A (zh) | 2018-05-09 | 2019-12-16 | 新旭生技股份有限公司 | 雜芳基化合物及其用途 |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SMT202500291T1 (it) * | 2019-01-31 | 2025-09-12 | Spinogenix Inc | Forme solide di un promotore di spinogenesi |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
| CN114728071B (zh) | 2019-11-13 | 2024-12-06 | 新旭生技股份有限公司 | 用于降解tau蛋白聚集体的化合物及其用途 |
| KR102426160B1 (ko) | 2020-07-13 | 2022-07-29 | (주)바이오액츠 | 알츠하이머 진단용 신규 형광화합물 및 이의 제조방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA241942A (en) | 1924-08-05 | Martinetto Vittorio | Asynchronous machine | |
| US2715629A (en) * | 1952-07-16 | 1955-08-16 | Du Pont | Sulfonic acid derivatives of 2-(4'-dialkylaminophenyl)-benzothiazole |
| LU37546A1 (2) * | 1958-08-22 | |||
| DE3148291A1 (de) | 1981-12-05 | 1983-06-09 | Basf Ag, 6700 Ludwigshafen | Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
| DE3307364A1 (de) * | 1983-03-02 | 1984-09-06 | Hoechst Ag, 6230 Frankfurt | Zweikomponenten-diazontypiematerial |
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| AU620327B2 (en) * | 1987-04-08 | 1992-02-20 | Salutar, Inc. | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor |
| US4933156A (en) * | 1987-04-08 | 1990-06-12 | Salutar, Inc. | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor |
| CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
| US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| US5297562A (en) | 1991-04-01 | 1994-03-29 | President And Fellows Of Harvard College | Method for detecting and treating Alzheimer's disease |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| GB9317949D0 (en) * | 1993-08-28 | 1993-10-13 | Stevens Malcolm F G | Benzothiazole compounds |
| AU692237B2 (en) | 1994-02-03 | 1998-06-04 | Picower Institute For Medical Research, The | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
| US6417178B1 (en) | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
| US6168776B1 (en) * | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| GB9503946D0 (en) * | 1995-02-28 | 1995-04-19 | Cancer Res Campaign Tech | Benzazole compounds |
| EP1110945A3 (en) | 1995-05-01 | 2003-05-07 | University Of Pittsburgh | Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| US6001331A (en) | 1996-01-24 | 1999-12-14 | Warner-Lambert Company | Method of imaging amyloid deposits |
| WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| TR199901132T2 (xx) | 1996-11-22 | 1999-08-23 | Elan Pharmaceuticals, Inc. | N-(aril/heteoaril) amino asit t�revleri, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| NZ504324A (en) * | 1997-11-20 | 2002-02-01 | Teijin Ltd | Biphenylamidine derivatives and pharmaceutical compositions thereof; which can be useful as anticoagulant inhibitors, and thrombus or embolus preventing agents |
| AU1089900A (en) | 1998-06-30 | 2000-01-24 | Kevin Mcclung | Controlled-penetration projectile |
| JP3820037B2 (ja) * | 1998-11-05 | 2006-09-13 | 三井化学株式会社 | 光記録媒体 |
| GB9919673D0 (en) * | 1999-08-20 | 1999-10-20 | Cancer Res Campaign Tech | 2-Arlybenzazole compounds |
| RU2324686C2 (ru) * | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| US7270800B2 (en) * | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| WO2002051821A1 (en) | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| CA2444214A1 (en) * | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| GB0229686D0 (en) | 2002-12-20 | 2003-01-29 | Amersham Plc | Solid-phase fluorination of benzothiazoles |
| PT1611115E (pt) * | 2003-03-14 | 2012-12-07 | Univ Pittsburgh | Compostos derivados de benzotiazole, composições e utilizações |
| US8236282B2 (en) * | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
| AU2005270026A1 (en) * | 2004-07-02 | 2006-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies |
| ATE539069T1 (de) * | 2005-10-11 | 2012-01-15 | Univ Pittsburgh | Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine |
-
2001
- 2001-08-24 RU RU2003108256/04A patent/RU2324686C2/ru not_active IP Right Cessation
- 2001-08-24 BR BR0113470-1 patent/BRPI0113470B8/pt not_active IP Right Cessation
- 2001-08-24 PT PT1966165T patent/PT1334091E/pt unknown
- 2001-08-24 AU AU8670201A patent/AU8670201A/xx active Pending
- 2001-08-24 AU AU2001286702A patent/AU2001286702B2/en not_active Expired
- 2001-08-24 SI SI200131017T patent/SI1334091T1/sl unknown
- 2001-08-24 CA CA2419420A patent/CA2419420C/en not_active Expired - Lifetime
- 2001-08-24 EP EP10185669.8A patent/EP2264018B1/en not_active Expired - Lifetime
- 2001-08-24 HU HU0302956A patent/HU230375B1/hu unknown
- 2001-08-24 US US09/935,767 patent/US20020133019A1/en not_active Abandoned
- 2001-08-24 CN CNB018178847A patent/CN1285582C/zh not_active Expired - Lifetime
- 2001-08-24 DK DK01966165.1T patent/DK1334091T3/da active
- 2001-08-24 ES ES01966165T patent/ES2395721T3/es not_active Expired - Lifetime
- 2001-08-24 HU HU1500560A patent/HU230581B1/hu unknown
- 2001-08-24 WO PCT/US2001/026427 patent/WO2002016333A2/en not_active Ceased
- 2001-08-24 PT PT101856698T patent/PT2264018E/pt unknown
- 2001-08-24 EP EP01966165A patent/EP1334091B1/en not_active Expired - Lifetime
- 2001-08-24 ES ES10185669.8T patent/ES2536449T3/es not_active Expired - Lifetime
- 2001-08-24 JP JP2002521434A patent/JP5022554B2/ja not_active Expired - Lifetime
- 2001-08-24 DK DK10185669.8T patent/DK2264018T3/en active
- 2001-08-24 PL PL360550A patent/PL215711B1/pl unknown
-
2003
- 2003-02-24 NO NO20030860A patent/NO330176B1/no not_active IP Right Cessation
-
2004
- 2004-06-03 US US10/859,600 patent/US7351401B2/en not_active Expired - Lifetime
-
2008
- 2008-03-11 US US12/046,070 patent/US20080154042A1/en not_active Abandoned
- 2008-06-13 AU AU2008202626A patent/AU2008202626B9/en not_active Expired
-
2011
- 2011-12-02 US US13/310,243 patent/US20120095235A1/en not_active Abandoned
- 2011-12-06 JP JP2011266396A patent/JP2012102106A/ja active Pending
-
2012
- 2012-11-06 CY CY20121101055T patent/CY1113311T1/el unknown
-
2015
- 2015-01-13 US US14/595,949 patent/US9833458B2/en not_active Expired - Fee Related
- 2015-01-19 LT LTPA2015001C patent/LTC1334091I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7351401B2 (en) | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | |
| US10137210B2 (en) | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | |
| AU2001286702A1 (en) | Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease | |
| AU2011200667A1 (en) | Benzothiazole derivative compounds, compositions and uses | |
| HK1146725B (en) | Thioflavin derivatives for use in the diagnosis of alzheimer's disease | |
| HK1058041B (en) | Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease | |
| HK1086270B (en) | Benzothiazole derivative compounds, compositions and uses | |
| CZ20001685A3 (cs) | Sloučeniny pro diagnózu Alzheimerovy nemoci a in vivo zobrazení a prevenci deposit amyloidu |